Litigation Details for Exela Pharma Sciences, LLC v. Sandoz, Inc. (D. Del. 2020)
✉ Email this page to a colleague
Exela Pharma Sciences, LLC v. Sandoz, Inc. (D. Del. 2020)
Docket | ⤷ Sign Up | Date Filed | 2020-05-14 |
Court | District Court, D. Delaware | Date Terminated | 2020-08-07 |
Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
Jury Demand | Plaintiff | Referred To | |
Patents | 10,478,453; 10,583,155 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Exela Pharma Sciences, LLC v. Sandoz, Inc.
Details for Exela Pharma Sciences, LLC v. Sandoz, Inc. (D. Del. 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2020-08-07 | 22 | Redacted Document | owner of U.S. Patent Nos. 10,478,453 (the “’453 patent”); 10,583,155 (the “’155 patent”), and 10,653,719…Sciences, LLC (“Exela”) filed the above-captioned patent litigation against Defendant Sandoz, Inc. (“Sandoz…10,653,719 (the “’719 patent); WHEREAS Exela is the holder of NDA No. 210660 for L-cysteine hydrochloride…Elcys®; WHEREAS the ’453,’155, and ’719 patents are listed in the Approved Drug Products with…and/or non-infringement of the ’453 and ’155 patents with respect to ANDA No. 209994 for L-cysteine | External link to document |
2020-05-14 | 5 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,478,453 ;10,583,155. (lak)…2020 7 August 2020 1:20-cv-00645 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |